The association of bone mineral density with HIV infection and antiretroviral treatment in women

Kathryn Anastos, Dalian Lu, Qiuhu Shi, Kathleen Mulligan, Phyllis C. Tien, Ruth Freeman, Mardge H. Cohen, Jessica Justman, Nancy A. Hessol

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background: Low bone mineral density (BMD) has been reported in HIV-infected women and men. Methods: We analysed cross-sectional BMD measured by regional dual X-ray absorptiometry at the lumbar spine (LS) and femoral neck (FN) in 152 HIV-negative and 274 HIV-positive (HIV+) women, adjusted for traditional low BMD risk factors. Results: BMD was significantly lower in protease inhibitor (Pl) users than in all other groups, and highest in HIV-negative women. In multivariate analyses the prevalence of T-score <-1.0 was significantly higher in the HIV+ women naive to antiretroviral therapy (ART; odds ratio [OR] 4.36, 95% confidence interval [CI] 1.61, 11.8) and the women receiving PI-containing HMRT (OR 3.72, CI 1.43, 9.68), with a non-significant difference in non-PI HAART users (OR 2.43, CI 0.92, 6.45), compared with HIV-negative women. In pair-wise adjusted comparisons, BMD was lower in ART-naive than in HIV-negative women (1.22 versus 1.30 g/cm2 at LS; P=0.004), in PI compared with non-PI HAART users (1.00 versus 1.05 g/cm2 at FN; P=0.014) and with those ART-naive (1.00 versus 1.03 g/cm2 at FN; P=0.146). Potential confounders, including duration of ART, prior treatment regimens and traditional risk factors for low BMD did not explain these differences. Longer lopinavir use was significantly correlated with lower BMD (r2=-0.39, P=0.024 and r2=-0.46, P=0.006 at LS and FN, respectively) and longer efavirenz use with higher BMD (r 2=+0.32. P=0.004 at FN). Conclusions: HIV infection was associated with lower BMD in women, independent of the traditional risk factors for low BMD. PI-containing HAART compared with non-PI-containing HAART, and longer lopinavir use, were both associated with lower BMD, and efavirenz use was associated with higher BMD.

Original languageEnglish (US)
Pages (from-to)1049-1058
Number of pages10
JournalAntiviral Therapy
Volume12
Issue number7
StatePublished - 2007

Fingerprint

Bone Density
HIV Infections
HIV
Femur Neck
efavirenz
Highly Active Antiretroviral Therapy
Therapeutics
Lopinavir
Spine
Odds Ratio
Confidence Intervals
Photon Absorptiometry
Protease Inhibitors
Multivariate Analysis

ASJC Scopus subject areas

  • Pharmacology

Cite this

Anastos, K., Lu, D., Shi, Q., Mulligan, K., Tien, P. C., Freeman, R., ... Hessol, N. A. (2007). The association of bone mineral density with HIV infection and antiretroviral treatment in women. Antiviral Therapy, 12(7), 1049-1058.

The association of bone mineral density with HIV infection and antiretroviral treatment in women. / Anastos, Kathryn; Lu, Dalian; Shi, Qiuhu; Mulligan, Kathleen; Tien, Phyllis C.; Freeman, Ruth; Cohen, Mardge H.; Justman, Jessica; Hessol, Nancy A.

In: Antiviral Therapy, Vol. 12, No. 7, 2007, p. 1049-1058.

Research output: Contribution to journalArticle

Anastos, K, Lu, D, Shi, Q, Mulligan, K, Tien, PC, Freeman, R, Cohen, MH, Justman, J & Hessol, NA 2007, 'The association of bone mineral density with HIV infection and antiretroviral treatment in women', Antiviral Therapy, vol. 12, no. 7, pp. 1049-1058.
Anastos, Kathryn ; Lu, Dalian ; Shi, Qiuhu ; Mulligan, Kathleen ; Tien, Phyllis C. ; Freeman, Ruth ; Cohen, Mardge H. ; Justman, Jessica ; Hessol, Nancy A. / The association of bone mineral density with HIV infection and antiretroviral treatment in women. In: Antiviral Therapy. 2007 ; Vol. 12, No. 7. pp. 1049-1058.
@article{92b3f7f4a5024c7c9edacfdcdf6f6eca,
title = "The association of bone mineral density with HIV infection and antiretroviral treatment in women",
abstract = "Background: Low bone mineral density (BMD) has been reported in HIV-infected women and men. Methods: We analysed cross-sectional BMD measured by regional dual X-ray absorptiometry at the lumbar spine (LS) and femoral neck (FN) in 152 HIV-negative and 274 HIV-positive (HIV+) women, adjusted for traditional low BMD risk factors. Results: BMD was significantly lower in protease inhibitor (Pl) users than in all other groups, and highest in HIV-negative women. In multivariate analyses the prevalence of T-score <-1.0 was significantly higher in the HIV+ women naive to antiretroviral therapy (ART; odds ratio [OR] 4.36, 95{\%} confidence interval [CI] 1.61, 11.8) and the women receiving PI-containing HMRT (OR 3.72, CI 1.43, 9.68), with a non-significant difference in non-PI HAART users (OR 2.43, CI 0.92, 6.45), compared with HIV-negative women. In pair-wise adjusted comparisons, BMD was lower in ART-naive than in HIV-negative women (1.22 versus 1.30 g/cm2 at LS; P=0.004), in PI compared with non-PI HAART users (1.00 versus 1.05 g/cm2 at FN; P=0.014) and with those ART-naive (1.00 versus 1.03 g/cm2 at FN; P=0.146). Potential confounders, including duration of ART, prior treatment regimens and traditional risk factors for low BMD did not explain these differences. Longer lopinavir use was significantly correlated with lower BMD (r2=-0.39, P=0.024 and r2=-0.46, P=0.006 at LS and FN, respectively) and longer efavirenz use with higher BMD (r 2=+0.32. P=0.004 at FN). Conclusions: HIV infection was associated with lower BMD in women, independent of the traditional risk factors for low BMD. PI-containing HAART compared with non-PI-containing HAART, and longer lopinavir use, were both associated with lower BMD, and efavirenz use was associated with higher BMD.",
author = "Kathryn Anastos and Dalian Lu and Qiuhu Shi and Kathleen Mulligan and Tien, {Phyllis C.} and Ruth Freeman and Cohen, {Mardge H.} and Jessica Justman and Hessol, {Nancy A.}",
year = "2007",
language = "English (US)",
volume = "12",
pages = "1049--1058",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "7",

}

TY - JOUR

T1 - The association of bone mineral density with HIV infection and antiretroviral treatment in women

AU - Anastos, Kathryn

AU - Lu, Dalian

AU - Shi, Qiuhu

AU - Mulligan, Kathleen

AU - Tien, Phyllis C.

AU - Freeman, Ruth

AU - Cohen, Mardge H.

AU - Justman, Jessica

AU - Hessol, Nancy A.

PY - 2007

Y1 - 2007

N2 - Background: Low bone mineral density (BMD) has been reported in HIV-infected women and men. Methods: We analysed cross-sectional BMD measured by regional dual X-ray absorptiometry at the lumbar spine (LS) and femoral neck (FN) in 152 HIV-negative and 274 HIV-positive (HIV+) women, adjusted for traditional low BMD risk factors. Results: BMD was significantly lower in protease inhibitor (Pl) users than in all other groups, and highest in HIV-negative women. In multivariate analyses the prevalence of T-score <-1.0 was significantly higher in the HIV+ women naive to antiretroviral therapy (ART; odds ratio [OR] 4.36, 95% confidence interval [CI] 1.61, 11.8) and the women receiving PI-containing HMRT (OR 3.72, CI 1.43, 9.68), with a non-significant difference in non-PI HAART users (OR 2.43, CI 0.92, 6.45), compared with HIV-negative women. In pair-wise adjusted comparisons, BMD was lower in ART-naive than in HIV-negative women (1.22 versus 1.30 g/cm2 at LS; P=0.004), in PI compared with non-PI HAART users (1.00 versus 1.05 g/cm2 at FN; P=0.014) and with those ART-naive (1.00 versus 1.03 g/cm2 at FN; P=0.146). Potential confounders, including duration of ART, prior treatment regimens and traditional risk factors for low BMD did not explain these differences. Longer lopinavir use was significantly correlated with lower BMD (r2=-0.39, P=0.024 and r2=-0.46, P=0.006 at LS and FN, respectively) and longer efavirenz use with higher BMD (r 2=+0.32. P=0.004 at FN). Conclusions: HIV infection was associated with lower BMD in women, independent of the traditional risk factors for low BMD. PI-containing HAART compared with non-PI-containing HAART, and longer lopinavir use, were both associated with lower BMD, and efavirenz use was associated with higher BMD.

AB - Background: Low bone mineral density (BMD) has been reported in HIV-infected women and men. Methods: We analysed cross-sectional BMD measured by regional dual X-ray absorptiometry at the lumbar spine (LS) and femoral neck (FN) in 152 HIV-negative and 274 HIV-positive (HIV+) women, adjusted for traditional low BMD risk factors. Results: BMD was significantly lower in protease inhibitor (Pl) users than in all other groups, and highest in HIV-negative women. In multivariate analyses the prevalence of T-score <-1.0 was significantly higher in the HIV+ women naive to antiretroviral therapy (ART; odds ratio [OR] 4.36, 95% confidence interval [CI] 1.61, 11.8) and the women receiving PI-containing HMRT (OR 3.72, CI 1.43, 9.68), with a non-significant difference in non-PI HAART users (OR 2.43, CI 0.92, 6.45), compared with HIV-negative women. In pair-wise adjusted comparisons, BMD was lower in ART-naive than in HIV-negative women (1.22 versus 1.30 g/cm2 at LS; P=0.004), in PI compared with non-PI HAART users (1.00 versus 1.05 g/cm2 at FN; P=0.014) and with those ART-naive (1.00 versus 1.03 g/cm2 at FN; P=0.146). Potential confounders, including duration of ART, prior treatment regimens and traditional risk factors for low BMD did not explain these differences. Longer lopinavir use was significantly correlated with lower BMD (r2=-0.39, P=0.024 and r2=-0.46, P=0.006 at LS and FN, respectively) and longer efavirenz use with higher BMD (r 2=+0.32. P=0.004 at FN). Conclusions: HIV infection was associated with lower BMD in women, independent of the traditional risk factors for low BMD. PI-containing HAART compared with non-PI-containing HAART, and longer lopinavir use, were both associated with lower BMD, and efavirenz use was associated with higher BMD.

UR - http://www.scopus.com/inward/record.url?scp=36148939489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36148939489&partnerID=8YFLogxK

M3 - Article

C2 - 18018763

AN - SCOPUS:36148939489

VL - 12

SP - 1049

EP - 1058

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 7

ER -